BIOABioAge Labs, Inc.

BIOA Stock Price, Valuation & Chart | BioAge Labs, Inc.

Compare

$9.730+0.21 (+2.21%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology BIOA intrinsic value BIOA calculated fair value vs price

Overview Financials Dividends Ratios

BIOA Historical price chart

BIOA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization366.33M

PE Ratio-4.09

EPS-2.38

Trading Volume540.77K

Today's High/Low10.05/9.43

Dividend Yield0.00

52 Week High/Low25.95/4.55

Shares Outstanding37.65M

BIOA Financial Statement

BIOA Analyst ratings

BIOA Analysis & performance metrics

BIOA Company profile

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and…

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical…

BIOA Management team

Name

Position

Carrie-Lynn Langlais Furr

Senior Vice President of Regulatory Affairs

Paul D. Rubin M.D.

Chief Medical Officer & Executive Vice President of Research

BJ Sullivan Ph.D.

Chief Strategy Officer

Julie Gammelgard

Senior Vice President of People

Peng Leong M.B.A., Ph.D.

Chief Business Officer & Therapeutic Area Head of Brain Aging

Justin Rebo

Senior Vice President of Translational Aging Biology

Dov A. Goldstein M.B.A., M.D.CFO

Chief Financial Officer

Eric Morgen M.D.COO

Co-Founder, Chief Operating Officer & Director

Name

Position

Carrie-Lynn Langlais Furr

Senior Vice President of Regulatory Affairs

Paul D. Rubin M.D.

Chief Medical Officer & Executive Vice President of Research

BJ Sullivan Ph.D.

Chief Strategy Officer

Julie Gammelgard

Senior Vice President of People

Peng Leong M.B.A., Ph.D.

Chief Business Officer & Therapeutic Area Head of Brain Aging

Justin Rebo

Senior Vice President of Translational Aging Biology

Dov A. Goldstein M.B.A., M.D.CFO

Chief Financial Officer

Eric Morgen M.D.COO

Co-Founder, Chief Operating Officer & Director

Management Team

Carrie-Lynn Langlais Furr

Senior Vice President of Regulatory Affairs

Paul D. Rubin M.D.

Chief Medical Officer & Executive Vice President of Research

BJ Sullivan Ph.D.

Chief Strategy Officer

Julie Gammelgard

Senior Vice President of People

Peng Leong M.B.A., Ph.D.

Chief Business Officer & Therapeutic Area Head of Brain Aging

Justin Rebo

Senior Vice President of Translational Aging Biology

Dov A. Goldstein M.B.A., M.D.CFO

Chief Financial Officer

Eric Morgen M.D.COO

Co-Founder, Chief Operating Officer & Director

Management

Carrie-Lynn Langlais Furr

Senior Vice President of Regulatory Affairs

Paul D. Rubin M.D.

Chief Medical Officer & Executive Vice President of Research

BJ Sullivan Ph.D.

Chief Strategy Officer

Julie Gammelgard

Senior Vice President of People

Peng Leong M.B.A., Ph.D.

Chief Business Officer & Therapeutic Area Head of Brain Aging

Justin Rebo

Senior Vice President of Translational Aging Biology

Dov A. Goldstein M.B.A., M.D.CFO

Chief Financial Officer

Eric Morgen M.D.COO

Co-Founder, Chief Operating Officer & Director

Total 8 executives

BIOA Frequently asked questions

What is BioAge Labs, Inc. (BIOA) Stock Price?

Current stock price of BioAge Labs, Inc. (BIOA) stock is $9.730. The stock price is +2.21% higher in the session. The intraday range can be seen from this page. Volume of BioAge Labs, Inc. (BIOA) stock is 540.77K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the BioAge Labs, Inc. (BIOA) stock price going up or down today?

The stock price of BioAge Labs, Inc. (BIOA) can change with earnings, company news, and overall market sentiment. BioAge Labs, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the BioAge Labs, Inc. stock expensive at its current price?

Whether BioAge Labs, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BIOA on this page is -4.09. EPS on this page is -2.38. Compare those figures with peers and growth expectations before deciding if the current BioAge Labs, Inc. price is justified.

How has the stock price of BioAge Labs, Inc. (BIOA) performed historically?

Historical performance for BioAge Labs, Inc. (BIOA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BIOA reacted to past earnings and market events.

Should I buy BioAge Labs, Inc. (BIOA) stock, at this price?

Buying BioAge Labs, Inc. (BIOA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.